Sio Gene Therapies Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
12
- Share Price
-
$0.48
- (As of Wednesday Closing)
Sio Gene Therapies General Information
Description
Sio Gene Therapies Inc is a clinical-stage company that is focused on gene therapy for neurodegenerative diseases. The company is developing its pipeline for the treatment of debilitating diseases, including Parkinson's disease, GM1 gangliosidosis, and GM2 gangliosidosis.
Contact Information
Website
www.siogtx.comCorporate Office
- 130 West 42nd Street
- 26th floor
- New York, NY 10036
- United States
Corporate Office
- 130 West 42nd Street
- 26th floor
- New York, NY 10036
- United States
Sio Gene Therapies Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.48 | $0.47 | $0.25 - $0.50 | $35.4M | 74M | 58.2K | -$0.39 |
Sio Gene Therapies Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 | FY 2020 31-Mar-2020 |
|---|---|---|---|---|
| EV | (17,682) | (29,859) | 65,491 | 85,109 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (27,930) | (70,935) | (29,372) | (64,719) |
| Net Income | (28,829) | (71,887) | (32,425) | (72,628) |
| Total Assets | 47,272 | 75,080 | 135,147 | 93,680 |
| Total Debt | 0 | 2,516 | 1,243 | 16,391 |
Sio Gene Therapies Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sio Gene Therapies Comparisons
Industry
Financing
Details
000000
000000
Sio Gene Therapies Competitors (13)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Catalyst Pharmaceuticals | Corporation | Coral Gables, FL | 000 | 00000 | 00000000 | 00000 |
| Regulus Therapeutics | Formerly VC-backed | San Diego, CA | 00 | 00000 | 00000000 | 00000 |
| Moderna | Formerly VC-backed | Cambridge, MA | 0000 | 00.000 | 000000000 | 00.000 |
| Omeros | Formerly VC-backed | Seattle, WA | 000 | 00000 | 000000000 00 | 00000 |
| Ipsen (Pharmaceuticals) | Formerly PE-Backed | Boulogne Billancourt, France | 0000 | 00000 | 000000000 | 00000 |
Sio Gene Therapies Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Sio Gene Therapies Patents
Sio Gene Therapies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3937985-A1 | Gene therapy compositions and methods for treating parkinson's disease | Inactive | 10-Mar-2019 | 0000000000 | |
| US-20220175962-A1 | Gene therapy compositions and methods for treating parkinson's disease | Pending | 10-Mar-2019 | 000000000 | |
| US-20190046506-A1 | Use of 5ht2a inverse agonists for treating psychosis | Inactive | 10-Aug-2017 | 0000000000 | |
| US-20210128528-A1 | Use of 5ht2a inverse agonists for treating psychosis | Inactive | 10-Aug-2017 | 0000000000 | 0 |
| US-20180042922-A1 | Compositions and methods of treating a neurodegenerative disease | Inactive | 15-Aug-2016 | A61K31/496 |
Sio Gene Therapies Executive Team (19)
| Name | Title | Board Seat |
|---|---|---|
| David Nassif JD | Chief Executive Officer & Chief Financial Officer, Finance | |
| Marianne Romeo | Board Member & Head, Risk Management & Global Transactions |
Sio Gene Therapies Board Members (19)
| Name | Representing | Role | Since |
|---|---|---|---|
| Berndt Modig | Self | Board Member | 000 0000 |
| Marianne Romeo | Sio Gene Therapies | Board Member & Head, Risk Management & Global Transactions | 000 0000 |
Sio Gene Therapies Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Sio Gene Therapies Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Sio Gene Therapies ESG
Risk Overview
Risk Rating
Updated June, 07, 2020
34.72 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
0.000
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 12,221
Rank
Percentile
Pharmaceuticals
Industry
00 of 709
Rank
Percentile
Biotechnology
Subindustry
00 of 343
Rank
Percentile
Sio Gene Therapies FAQs
-
When was Sio Gene Therapies founded?
Sio Gene Therapies was founded in 2014.
-
Who is the CEO of Sio Gene Therapies?
David Nassif JD is the CEO of Sio Gene Therapies.
-
Where is Sio Gene Therapies headquartered?
Sio Gene Therapies is headquartered in New York, NY.
-
What is the size of Sio Gene Therapies?
Sio Gene Therapies has 12 total employees.
-
What industry is Sio Gene Therapies in?
Sio Gene Therapies’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Sio Gene Therapies a private or public company?
Sio Gene Therapies is a Public company.
-
What is the current stock price of Sio Gene Therapies?
As of 07-Feb-2024 the stock price of Sio Gene Therapies is $0.48.
-
What is the current market cap of Sio Gene Therapies?
The current market capitalization of Sio Gene Therapies is $35.4M.
-
Who are Sio Gene Therapies’s competitors?
Catalyst Pharmaceuticals, Regulus Therapeutics, Moderna, Omeros, and Ipsen (Pharmaceuticals) are some of the 13 competitors of Sio Gene Therapies.
-
What is Sio Gene Therapies’s annual earnings per share (EPS)?
Sio Gene Therapies’s EPS for 12 months was -$0.39.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
